Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.

Tsuchiya N, Matsuyama R, Murakami T, Yabushita Y, Sawada YU, Kumamoto T, Endo I.

Anticancer Res. 2019 Aug;39(8):4431-4440. doi: 10.21873/anticanres.13615.

PMID:
31366541
2.

Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.

Fujii T, Satoi S, Yamada S, Murotani K, Yanagimoto H, Takami H, Yamamoto T, Kanda M, Yamaki S, Hirooka S, Kon M, Kodera Y.

J Gastroenterol. 2017 Jan;52(1):81-93. doi: 10.1007/s00535-016-1217-x. Epub 2016 May 11.

PMID:
27169844
3.

Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.

Kim NH, Kim HJ.

Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7.

PMID:
30237091
4.

Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.

Satoi S, Yanagimoto H, Yamamoto T, Ohe C, Miyasaka C, Uemura Y, Hirooka S, Yamaki S, Ryota H, Michiura T, Inoue K, Matsui Y, Tanigawa N, Kon M.

Surg Today. 2017 Jan;47(1):84-91. Epub 2016 Jun 4.

PMID:
27262676
5.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
6.

Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y, Tanaka K, Endo I.

Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.

PMID:
24310792
7.

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T, Ku Y.

Surg Today. 2016 May;46(5):583-92. doi: 10.1007/s00595-015-1206-3. Epub 2015 Jun 25.

PMID:
26108488
8.

[The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].

Sano T, Takano K, Chiba N, Tomita K, Ozawa Y, Hikita K, Shimazu M, Kawachi S.

Gan To Kagaku Ryoho. 2015 Nov;42(12):1488-90. Japanese.

PMID:
26805072
9.

Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.

Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS.

World J Gastroenterol. 2015 Mar 7;21(9):2711-8. doi: 10.3748/wjg.v21.i9.2711.

10.

Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?

Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M.

Surgery. 2012 Sep;152(3 Suppl 1):S112-9. doi: 10.1016/j.surg.2012.05.017. Epub 2012 Jul 3.

PMID:
22766365
11.

FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.

Akita H, Takahashi H, Ohigashi H, Tomokuni A, Kobayashi S, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, Miyata H, Ohue M, Fujiwara Y, Yano M, Ishikawa O, Sakon M.

Eur J Surg Oncol. 2017 Jun;43(6):1061-1067. doi: 10.1016/j.ejso.2017.03.015. Epub 2017 Mar 31.

PMID:
28389044
12.

Borderline resectable pancreatic cancer.

Hackert T, Ulrich A, Büchler MW.

Cancer Lett. 2016 Jun 1;375(2):231-237. doi: 10.1016/j.canlet.2016.02.039. Epub 2016 Mar 9. Review.

PMID:
26970276
13.

A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.

Dumont R, Puleo F, Collignon J, Meurisse N, Chavez M, Seidel L, Gast P, Polus M, Loly C, Delvenne P, Meunier P, Hustinx R, Deroover A, Detry O, Louis E, Martinive P, Van Daele D.

Acta Gastroenterol Belg. 2017 Oct-Dec;80(4):451-461. Review. Erratum in: Acta Gastroenterol Belg. 2018 Apr-Jun;81(2):358.

PMID:
29560639
14.

Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.

Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S, Kwon AH.

Pancreas. 2009 Apr;38(3):282-8. doi: 10.1097/MPA.0b013e31819438c3.

PMID:
19142173
15.

Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.

Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, Motoi F, Uemura K, Sho M, Satoi S, Honda G, Yamaue H, Unno M, Akahori T, Kwon AH, Kurata M, Ajiki T, Fukumoto T, Ku Y.

Pancreatology. 2015 Nov-Dec;15(6):674-80. doi: 10.1016/j.pan.2015.09.008. Epub 2015 Oct 3.

PMID:
26467797
16.

Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.

Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH, Cameron JL, Weiss MJ, Wolfgang CL, Herman JM, He J.

Surgery. 2018 May;163(5):1090-1096. doi: 10.1016/j.surg.2017.11.027. Epub 2018 Mar 12.

17.

Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?

Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D.

World J Surg Oncol. 2014 Nov 18;12:347. doi: 10.1186/1477-7819-12-347.

18.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
19.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Apr;22(4):1168-75. doi: 10.1245/s10434-014-4192-6. Epub 2014 Oct 29.

20.

Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.

Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Wakamatsu S, Hoshi S, Hoshi N, Hirabayashi K, Ogata Y.

Eur J Surg Oncol. 2017 Jun;43(6):1068-1075. doi: 10.1016/j.ejso.2017.03.020. Epub 2017 Apr 8.

PMID:
28427822

Supplemental Content

Support Center